List view / Grid view
This webinar, supported by Tecan, focused on the automated assessment of liver and cardiac toxicities in lead optimisation, using biochemical and human iPS cell assays.
27 April 2018 | By TECAN
ABOUT THIS WEBINAR: In this two-part webinar, both automation of P450 (CYP) assays and the automatisation of cellular differentiation processes and compound testing using human induced pluripotent stem cells based assays was covered. Metabolism of drugs is a key factor in compound toxicity, and automated assays which monitor inhibition or…
Declining R&D productivity is a key challenge in the pharmaceutical industry. To increase the success rate of candidate drugs entering the clinical phase, companies must address the early stages of drug discovery.
In this issue: how customised cell engineering advances immunotherapy, how insights into auto-immunity are providing new opportunities for immune-oncology, and advances in lab automation and robotics are accelerating the pace of antimicrobial therapy.
1 February 2018 | By PerkinElmer
This webinar discussed a screening assay that recapitulates the activation of ER stress sensor IRE1 and an assay to quantify cell migration phenotypes, as applied to cardiovascular target validation and drug discovery.
Neglected tropical diseases (NTD) affect more than one billion people and new targets and drugs are needed to tackle these infections. The multi-disciplinary NMTrypI consortium has identified a number of different compound classes which could be effective against these diseases. This article reviews some of these compounds...
Hits identified in high-throughput screens are evaluated within the hit-to-lead phase of drug discovery, where they undergo an iterative optimisation process employing a variety of techniques to identify promising lead compounds to move forward to the lead optimisation phase.
Declining R&D productivity is a key challenge in the pharmaceutical industry today.
In this In-Depth Focus we look at a pragmatic approach to hit validation following biochemical high-throughput screening as well as identification of hits and leads for human African trypanosomiasis.
Issue 4 of Drug Target Review looks at artificial intelligence in drug discovery and features In-Depth Focuses on Screening, Hit to Lead and Informatics.
SMi are delighted to have, Nagy Habib, Head of HPB Surgery, Imperial College London and Co-Founder, MiNA Therapeutics, as the Keynote Address for day 1 at RNA Therapeutics 2018!
A protein has been identified as a possible cause for the adverse reaction of the immune system in patients suffering from lupus.
30 June 2017 | By PerkinElmer
In this webinar, PerkinElmer and AMRI will present a case study wherein high-performance computing (HPC) was leveraged for enhanced performance in image and data analysis of High Content Screening experiments...
Research into innovative small molecule therapeutics with disease modifying potential in Alzheimer’s disease (AD) has been conducted at Alzheon since 2013.
BenevolentAI, a British artificial intelligence company, has partnered with MRC Technology (MRCT), a medical research charity, to explore drug discovery initiatives in the field of small molecules and antibodies.
